New Phase 3 trial: Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease — Pfizer
Why now
Thesis: Incremental vaccine label expansion, slow-burn
Catalyst to watch: Trial enrollment and safety review milestones
Main risk: Pediatric RSV efficacy may underwhelm
Why it matters
Pfizer's RSVpreF pediatric study targets a high-risk population, an incremental expansion of an existing vaccine franchise.
Details
Sponsor: Pfizer; Status: Not Yet Recruiting; Conditions: Respiratory Syncytial Virus (RSV); Interventions: RSVpreF, Placebo; Enrollment: 920 (estimated); First posted: 2026-09-24; NCT: NCT07839871
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-24 12:00 UTC